Regorafenib, an investigational agent for the treatment of cholangiocarcinoma

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. CA Cancer J Clin. 2020;70(1):7–30.
   PubMed Web of Science ®Google Scholar
• Florio AA, Ferlay J, Znaor A, et al. Global trends in intrahepatic and extrahepatic cholangiocarcinoma incidence from 1993 to 2012. Cancer. 2020;126(11):2666–2678.
   PubMed Web of Science ®Google Scholar
• Khan SA, Thomas HC, Davidson BR, et al. Cholangiocarcinoma. Lancet. 2005;366(9493):1303–1314.
   PubMed Web of Science ®Google Scholar
• Valle J, Wasan H, Palmer DH, et al. Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer. N Engl J Med. 2010;362(14):1273–1281.
   PubMed Web of Science ®Google Scholar
• Lowery MA, Ptashkin R, Jordan E, et al. Comprehensive molecular profiling of intrahepatic and extrahepatic cholangiocarcinomas: potential targets for intervention. Clin Cancer Res. 2018;24(17):4154–4161.
   PubMed Web of Science ®Google Scholar
• Chung HC, Ros W, Delord J-P, et al. Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study. J clin oncol. 2019;37(17):1470–1478.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Sahai V, Hollebecque A, et al. Pemigatinib for previously treated, locally advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 study. Lancet Oncol. 2020;21(5):671–684.
   Web of Science ®Google Scholar
• Lowery MA, Burris III HA, Janku F, et al. Safety and activity of ivosidenib in patients with IDH1-mutant advanced cholangiocarcinoma: a phase 1 study. Lancet Gastroenterol Hepatol. 2019;4(9):711–720.
   PubMed Web of Science ®Google Scholar
• Abou-Alfa GK, Macarulla T, Javle MM, et al. Ivosidenib in IDH1-mutant, chemotherapy-refractory cholangiocarcinoma (ClarIDHy): a multicentre, randomised, double-blind, placebo-controlled, phase 3 study. Lancet Oncol. 2020;21(6):796–807.
   Web of Science ®Google Scholar
• Drilon A, Laetsch TW, Kummar S, et al. Efficacy of larotrectinib in TRK fusion–positive cancers in adults and children. N Engl J Med. 2018;378(8):731–739.
   PubMed Web of Science ®Google Scholar
• Doebele RC, Drilon A, Paz-Ares L, et al. Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1–2 trials. Lancet Oncol. 2020;21(2):271–282.
   PubMed Web of Science ®Google Scholar
• Goel G. Evolution of regorafenib from bench to bedside in colorectal cancer: is it an attractive option or merely a “me too” drug? Cancer Manag Res. 2018;10:425.
   PubMed Web of Science ®Google Scholar
• Bengala C, Bertolini F, Malavasi N, et al. Sorafenib in patients with advanced biliary tract carcinoma: a phase II trial. Br J Cancer. 2010;102(1):68–72.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Rankin CJ, Ben-Josef E, et al. SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. Invest New Drugs. 2012;30(4):1646–1651.
   PubMed Web of Science ®Google Scholar
• Pan TT, Wang W, Jia WD, et al. A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. Oncol Lett. 2017;13(5):2957–2964.
   PubMed Web of Science ®Google Scholar
• Luo X, Jia W, Huang Z, et al. Effectiveness and safety of sorafenib in the treatment of unresectable and advanced intrahepatic cholangiocarcinoma: a pilot study. Oncotarget. 2017;8(10):17246–17257.
   PubMedGoogle Scholar
• Neuzillet C, Seitz J-F, Fartoux L, et al. Sunitinib as second-line treatment in patients with advanced intrahepatic cholangiocarcinoma (SUN-CK phase II trial): safety, efficacy, and updated translational results. J clin oncol. 2015;33(3_suppl):343.
   Web of Science ®Google Scholar
• Shroff RT, Yarchoan M, O’Connor A, et al. The oral VEGF receptor tyrosine kinase inhibitor pazopanib in combination with the MEK inhibitor trametinib in advanced cholangiocarcinoma. Br J Cancer. 2017;116(11):1402–1407. .
   PubMed Web of Science ®Google Scholar
• Lindsey S, Langhans SA. Epidermal growth factor signaling in transformed cells. Int Rev Cell Mol Biol. 2015;314:1–41.
   PubMed Web of Science ®Google Scholar
• Yoshikawa D, Ojima H, Iwasaki M, et al. Clinicopathological and prognostic significance of EGFR, VEGF, and HER2 expression in cholangiocarcinoma. Br J Cancer. 2008;98(2):418–425.
   PubMed Web of Science ®Google Scholar
• Clapéron A, Mergey M, Nguyen Ho-Bouldoires TH, et al. EGF/EGFR axis contributes to the progression of cholangiocarcinoma through the induction of an epithelial-mesenchymal transition. J Hepatol. 2014;61(2):325–332.
   PubMed Web of Science ®Google Scholar
• Sha M, Jeong S, Chen XS, et al. Expression of VEGFR-3 in intrahepatic cholangiocarcinoma correlates with unfavorable prognosis through lymphangiogenesis. Int J Biol Sci. 2018;14(10):1333.
   PubMed Web of Science ®Google Scholar
• Peng H, Zhang Q, Li J, et al. Apatinib inhibits VEGF signaling and promotes apoptosis in intrahepatic cholangiocarcinoma. Oncotarget. 2016;7(13):17220.
   PubMedGoogle Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2-PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6:6087.
   PubMed Web of Science ®Google Scholar
• Arai Y, Totoki Y, Hosoda F, et al. Fibroblast growth factor receptor 2 tyrosine kinase fusions define a unique molecular subtype of cholangiocarcinoma. Hepatology. 2014;59(4):1427–1434.
   PubMed Web of Science ®Google Scholar
• Sia D, Losic B, Moeini A, et al. Massive parallel sequencing uncovers actionable FGFR2–PPHLN1 fusion and ARAF mutations in intrahepatic cholangiocarcinoma. Nat Commun. 2015;6(1):1–11.
   Web of Science ®Google Scholar
• Fingas CD, Bronk SF, Werneburg NW, et al. Myofibroblast-derived PDGF-BB promotes Hedgehog survival signaling in cholangiocarcinoma cells. Hepatology. 2011;54(6):2076–2088.
   PubMed Web of Science ®Google Scholar
• Fingas CD, Mertens JC, Razumilava N, et al. Targeting PDGFR‐β in Cholangiocarcinoma. Liver Int. 2012;32(3):400–409.
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, et al. Regorafenib (BAY 73‐4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer. 2011;129(1):245–255.
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S, et al. A phase I dose–escalation study of regorafenib (BAY 73–4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res. 2012;18(9):2658–2667.
   PubMed Web of Science ®Google Scholar
• Sun W, Patel A, Normolle D, et al. A phase 2 trial of regorafenib as a single agent in patients with chemotherapy‐refractory, advanced, and metastatic biliary tract adenocarcinoma. Cancer. 2019;125(6):902–909.
   PubMed Web of Science ®Google Scholar
• Kim RD, Sanoff HK, Poklepovic AS, et al. A multi‐institutional phase 2 trial of regorafenib in refractory advanced biliary tract cancer. Cancer. 2020.
   PubMed Web of Science ®Google Scholar
• Demols A, Borbath I, Van den Eynde M, et al. Regorafenib after failure of gemcitabine and platinum-based chemotherapy for locally advanced/metastatic biliary tumors: a randomized, double-blind, phase 2 trial–REACHIN. Ann Oncol. 2020;31(9):1169–1177.
   PubMed Web of Science ®Google Scholar
• Roodhart JM, Langenberg MH, Witteveen E, et al. The molecular basis of class side effects due to treatment with inhibitors of the VEGF/VEGFR pathway. Curr Clin Pharmacol. 2008;3(2):132–143.
   PubMedGoogle Scholar
• Demetri GD, Reichardt P, Kang Y-K, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):295–302. .
   PubMed Web of Science ®Google Scholar
• Skårderud MR, Polk A, Vistisen KK, et al. Efficacy and safety of regorafenib in the treatment of metastatic colorectal cancer: a systematic review. Cancer Treat Rev. 2018;62:61–73.
   PubMed Web of Science ®Google Scholar
• George S, Wang Q, Heinrich MC, et al. Efficacy and safety of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of imatinib and sunitinib: a multicenter phase II trial. J clin oncol. 2012;30(19):2401.
   PubMed Web of Science ®Google Scholar
• Lipworth AD, Robert C, Zhu AX. Hand-foot syndrome (hand-foot skin reaction, palmar-plantar erythrodysesthesia): focus on sorafenib and sunitinib. Oncology. 2009;77(5):257–271.
   PubMed Web of Science ®Google Scholar
• Belum VR, Wu S, Lacouture ME. Risk of hand-foot skin reaction with the novel multikinase inhibitor regorafenib: a meta-analysis. Invest New Drugs. 2013;31(4):1078–1086.
   PubMed Web of Science ®Google Scholar
• McLellan B, Ciardiello F, Lacouture M, et al. Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26(10):2017–2026.
   PubMed Web of Science ®Google Scholar
• Strumberg D, Schultheis B. Regorafenib for cancer. Expert Opin Investig Drugs. 2012;21(6):879–889.
   PubMed Web of Science ®Google Scholar
• Grothey A, George S, Van Cutsem E, et al. Optimizing treatment outcomes with regorafenib: personalized dosing and other strategies to support patient care. Oncologist. 2014;19(6):669.
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet. 2013;381(9863):303–312.
   PubMed Web of Science ®Google Scholar
• Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma. N Engl J Med. 2020;382(20):1894–1905.
   PubMed Web of Science ®Google Scholar
• El-Khoueiry AB, Kim RD, Harris WP et al. Phase Ib study of regorafenib (REG) plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC). 2020.
   Google Scholar
• Isomoto K, Haratani K, Hayashi H, et al. Impact of EGFR-TKI treatment on the tumor immune microenvironment in EGFR mutation–positive non–small cell lung cancer. Clin Cancer Res. 2020;26(8):2037–2046.
   PubMed Web of Science ®Google Scholar
• Rassy E, Flippot R, Albiges L. Tyrosine kinase inhibitors and immunotherapy combinations in renal cell carcinoma. Ther Adv Med Oncol. 2020;12:1758835920907504.
   Web of Science ®Google Scholar
• Fukuoka S, Hara H, Takahashi N, et al. Regorafenib plus nivolumab in patients with advanced gastric or colorectal cancer: an open-label, dose-escalation, and dose-expansion phase IB trial (REGONIVO, EPOC1603). J Clin Oncol. 2020;19:03296.
   Google Scholar
• Le DT, Uram JN, Wang H, et al. PD-1 blockade in tumors with mismatch-repair deficiency. N Engl J Med. 2015;372(26):2509–2520.
   PubMed Web of Science ®Google Scholar
• Kim R, Imanirad I, Carballido E, et al. O-20 Phase I/IB study of regorafenib and nivolumab in mismatch repair proficient advanced refractory colorectal cancer. Ann Oncol. 2020;31:239.
   Web of Science ®Google Scholar
• Zhu AX, Finn RS, Ikeda M et al. A phase IB study of lenvatinib (LEN) plus pembrolizumab (PEMBRO) in unresectable hepatocellular carcinoma (uHCC). 2020.
   Google Scholar
• Kim RD, Chung V, Alese OB, et al. A phase 2 multi-institutional study of nivolumab for patients with advanced refractory biliary tract cancer. JAMA Oncol. 2020;6(6):888.
   Web of Science ®Google Scholar
• Marabelle A, Le DT, Ascierto PA, et al. Efficacy of pembrolizumab in patients with noncolorectal high microsatellite instability/mismatch repair–deficient cancer: results from the phase II KEYNOTE-158 study. J clin oncol. 2020;38(1):1–10.
   PubMed Web of Science ®Google Scholar
• Subbiah V, Lassen U, Élez E, et al. Dabrafenib plus trametinib in patients with BRAFV600E-mutated biliary tract cancer (ROAR): a phase 2, open-label, single-arm, multicentre basket trial. Lancet Oncol. 2020;21(9):1234–1243.
   Web of Science ®Google Scholar
• Sumimoto H, Imabayashi F, Iwata T, et al. The BRAF–MAPK signaling pathway is essential for cancer-immune evasion in human melanoma cells. J Exp Med. 2006;203(7):1651–1656.
   PubMed Web of Science ®Google Scholar